Alkem Laboratories Limited (ALKEM.BO)
INR 4835.45
(2.88%)
INR 4835.45
(2.88%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 19.46 Billion INR | 47.48% |
| 2022 | 13.19 Billion INR | -24.3% |
| 2021 | 17.43 Billion INR | 4.14% |
| 2020 | 16.73 Billion INR | 32.22% |
| 2019 | 12.66 Billion INR | 34.44% |
| 2018 | 9.41 Billion INR | 4.84% |
| 2017 | 8.98 Billion INR | -1.39% |
| 2016 | 9.1 Billion INR | 18.18% |
| 2015 | 7.7 Billion INR | 105.76% |
| 2014 | 3.74 Billion INR | 1.03% |
| 2013 | 3.7 Billion INR | -13.47% |
| 2012 | 4.28 Billion INR | 13.06% |
| 2011 | 3.79 Billion INR | 33.84% |
| 2010 | 2.83 Billion INR | 44.5% |
| 2009 | 1.95 Billion INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 5.28 Billion INR | 65.8% |
| 2023 Q1 | 3.16 Billion INR | -7.81% |
| 2023 FY | 19.46 Billion INR | 47.48% |
| 2023 Q3 | 7.31 Billion INR | -0.59% |
| 2023 Q4 | 3.18 Billion INR | -56.46% |
| 2023 Q2 | 7.36 Billion INR | 132.34% |
| 2022 Q2 | 4.27 Billion INR | 236.42% |
| 2022 Q4 | 3.43 Billion INR | -39.29% |
| 2022 FY | 13.19 Billion INR | -24.3% |
| 2022 Q1 | 1.26 Billion INR | -48.87% |
| 2022 Q3 | 5.65 Billion INR | 32.48% |
| 2021 FY | 17.43 Billion INR | 4.14% |
| 2021 Q4 | 2.48 Billion INR | -41.01% |
| 2021 Q3 | 4.2 Billion INR | -23.67% |
| 2021 Q1 | 5.22 Billion INR | 130.92% |
| 2021 Q2 | 5.51 Billion INR | 5.59% |
| 2020 Q3 | 4.6 Billion INR | -13.23% |
| 2020 Q2 | 5.3 Billion INR | 13.7% |
| 2020 Q1 | 4.66 Billion INR | 69.97% |
| 2020 FY | 16.73 Billion INR | 32.22% |
| 2020 Q4 | 2.26 Billion INR | -50.84% |
| 2019 FY | 12.66 Billion INR | 34.44% |
| 2019 Q3 | 3.93 Billion INR | -0.61% |
| 2019 Q2 | 3.96 Billion INR | 89.86% |
| 2019 Q1 | 2.08 Billion INR | 2.12% |
| 2019 Q4 | 2.74 Billion INR | -30.33% |
| 2018 FY | 9.41 Billion INR | 4.84% |
| 2018 Q4 | 2.04 Billion INR | -22.63% |
| 2018 Q3 | 2.64 Billion INR | -17.06% |
| 2018 Q2 | 3.18 Billion INR | 85.35% |
| 2018 Q1 | 1.71 Billion INR | 133.97% |
| 2017 Q4 | 734.2 Million INR | -77.22% |
| 2017 FY | 8.98 Billion INR | -1.39% |
| 2017 Q1 | 637.4 Million INR | -48.13% |
| 2017 Q2 | 4.25 Billion INR | 568.17% |
| 2017 Q3 | 3.22 Billion INR | -24.32% |
| 2016 FY | 9.1 Billion INR | 18.18% |
| 2016 Q3 | 2.41 Billion INR | -15.17% |
| 2016 Q4 | 1.22 Billion INR | -49.17% |
| 2016 Q1 | 2.48 Billion INR | 88.39% |
| 2016 Q2 | 2.84 Billion INR | 14.85% |
| 2015 Q1 | 1.85 Billion INR | 32.37% |
| 2015 Q2 | 2.29 Billion INR | 23.66% |
| 2015 FY | 7.7 Billion INR | 105.76% |
| 2015 Q4 | 1.31 Billion INR | -37.56% |
| 2015 Q3 | 2.1 Billion INR | -8.1% |
| 2014 Q1 | 872.75 Million INR | 0.0% |
| 2014 FY | 3.74 Billion INR | 1.03% |
| 2014 Q4 | 1.4 Billion INR | -6.43% |
| 2014 Q2 | 872.75 Million INR | 0.0% |
| 2014 Q3 | 1.49 Billion INR | 71.7% |
| 2013 FY | 3.7 Billion INR | -13.47% |
| 2012 FY | 4.28 Billion INR | 13.06% |
| 2011 FY | 3.79 Billion INR | 33.84% |
| 2010 FY | 2.83 Billion INR | 44.5% |
| 2009 FY | 1.95 Billion INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | -237.992% |
| Aurobindo Pharma Limited | 42.2 Billion INR | 53.885% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | -116.744% |
| Granules India Limited | 6.81 Billion INR | -185.503% |
| Indoco Remedies Limited | 1.29 Billion INR | -1405.699% |
| Achyut Healthcare Limited | 4.43 Million INR | -438428.616% |
| Ajanta Pharma Limited | 19.67 Billion INR | 1.095% |
| Alpa Laboratories Limited | 184.49 Million INR | -10448.627% |
| Brooks Laboratories Limited | 14.44 Million INR | -134677.701% |
| AstraZeneca Pharma India Limited | 1.71 Billion INR | -1033.153% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -1480.982% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 71.265% |
| Eris Lifesciences Limited | 5.18 Billion INR | -275.588% |
| FDC Limited | 2.98 Billion INR | -551.726% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | -199.304% |
| Gufic Biosciences Limited | 1.32 Billion INR | -1363.4% |
| Ind-Swift Laboratories Limited | 4.42 Billion INR | -340.26% |
| Ipca Laboratories Limited | 7.98 Billion INR | -143.865% |
| Jagsonpal Pharmaceuticals Limited | 508.13 Million INR | -3730.103% |
| Krebs Biochemicals & Industries Limited | -151.95 Million INR | 12907.505% |
| Lasa Supergenerics Limited | -458 Million INR | 4349.277% |
| Laurus Labs Limited | 3.94 Billion INR | -392.881% |
| Lupin Limited | 28.04 Billion INR | 30.604% |
| Mankind Pharma Limited | 21.51 Billion INR | 9.555% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Medico Remedies Limited | 100.3 Million INR | -19303.689% |
| Megasoft Limited | -121.1 Million INR | 16170.402% |
| NATCO Pharma Limited | 25.96 Billion INR | 25.037% |
| Piramal Pharma Limited | 4.55 Billion INR | -327.086% |
| RPG Life Sciences Limited | 2.29 Billion INR | -749.012% |
| Sigachi Industries Limited | 1.47 Billion INR | -1220.439% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 81.341% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | -322.383% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -7708.153% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Wanbury Limited | 569.71 Million INR | -3316.07% |
| Windlas Biotech Limited | 1.29 Billion INR | -1398.349% |
| ZIM Laboratories Limited | 253.82 Million INR | -7567.327% |
| Zydus Lifesciences Limited | 43.1 Billion INR | 54.852% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 572.945% |
| Divi's Laboratories Limited | 33.08 Billion INR | 41.167% |
| Hester Biosciences Limited | 364.81 Million INR | -5234.804% |
| Procter & Gamble Health Limited | 2.78 Billion INR | -598.561% |
| Amrutanjan Health Care Limited | 457.54 Million INR | -4153.558% |
| Bal Pharma Limited | 233.9 Million INR | -8220.287% |
| Strides Pharma Science Limited | 5.22 Billion INR | -272.419% |
| Venus Remedies Limited | 534.65 Million INR | -3540.113% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | -522.16% |
| Nectar Lifesciences Limited | 923.8 Million INR | -2006.709% |
| Shilpa Medicare Limited | 1.36 Billion INR | -1324.453% |
| Aarti Drugs Limited | 7.14 Billion INR | -172.243% |
| IOL Chemicals and Pharmaceuticals Limited | 1.59 Billion INR | -1118.806% |
| Suven Life Sciences Limited | -1.22 Billion INR | 1687.661% |
| Ind-Swift Limited | 1.22 Billion INR | -1487.477% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| J. B. Chemicals & Pharmaceuticals Limited | 14.28 Billion INR | -36.261% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 605.123% |
| Themis Medicare Limited | 392.58 Million INR | -4857.322% |
| Hikal Limited | 32.11 Million INR | -60510.09% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 23.182% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Novartis India Limited | 626.5 Million INR | -3006.449% |
| Wockhardt Limited | -670 Million INR | 3004.761% |
| Jubilant Pharmova Limited | 5.18 Billion INR | -275.061% |
| Biofil Chemicals and Pharmaceuticals Limited | 9.06 Million INR | -214505.18% |
| Neuland Laboratories Limited | 5.31 Billion INR | -265.956% |
| Morepen Laboratories Limited | 4.17 Billion INR | -366.284% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -9254.434% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -70778.797% |